NDATOPICALCREAM
Approved
Sep 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
TAZORAC (tazarotene) by Almirall. Approved for retinoid [epc]. First approved in 2000.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAZORAC (tazarotene) is a topical retinoid that binds to retinoic acid receptors (RAR) with selectivity for RARβ and RARγ, modifying gene expression. It is approved for acne vulgaris and psoriasis, with emerging clinical interest in idiopathic pulmonary fibrosis. The mechanism in acne involves anti-hyperproliferative, normalizing-of-differentiation, and anti-inflammatory effects on keratinocytes.
$2MPart D
LOE ApproachingDeclining
Approaching loss of exclusivity with minimal Part D utilization signals a mature, lower-priority asset with limited team expansion opportunity.
Mechanism of Action
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
Started Dec 2019
8 enrolled
Solid TumorHand-Foot Skin Reaction (HFSR)
A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris
Started Oct 2017
58 enrolled
Acne Vulgaris
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
Started Aug 2017
155 enrolled
Acne Vulgaris
Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream
Started Jun 2016
48 enrolled
Acne
Worked on TAZORAC at Almirall? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.